Therapy
Biotechnology
Medical

Adaptimmune Therapeutics

$3.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-2.83%) Today
-$0.11 (-2.83%) Today

Why Robinhood?

You can buy or sell ADAP and other stocks, options, ETFs, and crypto commission-free!

About

Adaptimmune Therapeutics plc American Depositary Shares, also called Adaptimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Read More The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Employees
430
Headquarters
Abingdon, Oxfordshire
Founded
2014
Market Cap
406.80M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
471.76K
High Today
$3.89
Low Today
$3.75
Open Price
$3.84
Volume
50.89K
52 Week High
$14.63
52 Week Low
$3.60

Collections

Therapy
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Cancer Prevention
Health
Technology

News

MarketBeatMar 5

Stock Price, News, & Analysis for Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform.

88
Seeking AlphaFeb 28

Adaptimmune Therapeutics (ADAP) CEO James Noble on Q4 2018 Results - Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2018 Results Earnings Conference Call February 27, 2019 8:00 PM ET Company Participants Juli Miller - IR James Noble - CEO Helen Tayton-Martin - Chief Business Officer Adrian Rawcliffe - CFO Rafael Amado - President, Research and Development Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Sun Trust Robinson Michael Schmidt - Guggenheim Securities Marc Frahm - Cowen & Company Reni Benjamin - Raymond James Soumit Roy - Jones T...

290
Associated PressFeb 27

CORRECTING and REPLACING -- Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. PHILADELPHIA and OXFORD, United Kingdom, Feb. 27, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Adaptimmune Therapeutics plc (Nasdaq:ADAP), please note that the third subheadline should ...

30

Earnings

-$0.32
-$0.21
-$0.10
$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.